Skeletal Kinetics LLC, developed, manufactures and markets Callos®, a proprietary next generation calcium phosphate bone fixation cement designed for use in regions of compromised cancellous bone resulting from trauma fractures. Cancellous (or spongy) bone is situated principally at the ends of long bones beneath joint surfaces, including areas such as the wrist, hip and knee. Cancellous bone is also found in the spine.

Callos can be used independently or together with conventional orthopedic fixation hardware devices such as implantable plates, screws, rods and wires.

Within the U.S. trauma market, there are more than 6 million fractures in the United States every year, with nearly 1.4 million fractures in cancellous bone treated surgically by orthopedic surgeons. Callos has received 510(k) marketing clearance from the U.S. Food and Drug Administration for treating all cancellous bone voids below the neck and for neuro-craniomaxillofacial (head and face) applications. Callos has also received the right to affix the CE mark for marketing to the European community.

Skeletal Kinetics currently distributes Callos in the U.S. and worldwide through corporate partners and independent sales agents and distributors.

There are eight issued U.S. patents covering the Callos technology, with corresponding world patent application, several pending U.S. and international patent applications, and several new cases in preparation addressing novel chemistries, cement delivery technology, and incorporation of biologic agents into biologic cements.

In August 2006 Skeletal Kinetics was aquired by the worldwide business group Colson Associates, Inc. which has a 60-year history in companies that include caster wheels, plastics, hardware and more recently, medical products. Skeletal Kinetics maintains its headquarters, engineering and manufacturing facility in Cupertino, California (in the heart of the Silicon Valley).